Drug updated on 10/28/2024
| Dosage Form | Solution (oral; 10 g/packet, 280 g/bottle, 560 g/bottle) |
| Drug Class | Osmotic laxatives |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Lactitol was found to be more effective than placebo in treating constipation in elderly patients over 65 years old, demonstrating short-term effectiveness (up to 3 months) along with other laxatives like psyllium, calcium polycarbophil, lactulose syrup, and polyethylene glycol.
- Lactitol and other laxatives reviewed, including polyethylene glycol, showed comparable efficacy, with polyethylene glycol standing out for its effectiveness in long-term use (up to 6 months).
- Lactitol, along with other laxatives like psyllium, calcium polycarbophil, lactulose syrup, and polyethylene glycol, showed similar frequency and severity of adverse effects compared to placebo. The overall safety profile was deemed reasonable for short-term use (up to 3 months).
- No specific safety concerns or severe adverse effects were highlighted for lactitol or any of the other laxatives reviewed, with no significant differences in safety outcomes observed among these drugs.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pizensy (lactitol) Prescribing Information. | 2021 | Braintree Laboratories, Inc., Braintree, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Medical Management of Constipation in Elderly Patients: Systematic Review | 2021 | Journal of Neurogastroenterology and Motility |